Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly and Co. reported strong performance in Q2 2025, exceeding expectations on both revenue and earnings while raising full-year guidance, signaling robust operational growth. Sales of the obesity treatment Mounjaro saw remarkable international growth of 60% quarter-over-quarter, and projections indicate continued strong sales growth and a significant increase in earnings per share by 2026. Additionally, the anticipated launch of orforglipron, an oral GLP-1 treatment, is expected to enhance the market for diabetes and obesity medications, further solidifying Eli Lilly's competitive position in its key therapeutic areas.

Bears say

Eli Lilly and Co faces significant downside risks that could negatively impact its stock performance, primarily due to potential pricing and rebate pressures which could compress profit margins. The company is experiencing a worse-than-expected prescription trajectory for tirzepatide, with its failure to demonstrate cardiac outcome benefits in key patient groups further complicating its commercial prospects. Additionally, the anticipated negative impact on Zepbound prescriptions and the increasing competition from orforglipron, which poses a threat to its market share, contribute to a bearish outlook on the company's financial health.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,109.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,109.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.